As a selective and ATP-compeitive inhibitor, SNX-2112 can inhibit HSP90alpha and HSP90beta with Ka of 30 nM and 30 nM by competitively binding to the N-terminal adenosine triphosphate binding site of Hsp90. SNX-2112 inhibits cell proliferatin of BT474, SKBR-3, SKOV-3, MDA-468, MCF-7 and H1650 cancer cells with IC50 from 10 to 50 nM.SNX-2112 also can induces cell apoptosis by inducing caspase-8, -9, -3, and poly (ADPribose) polymerase cleavage. ERK and Akt can be activated by SNX-2112. By abrogating eNOS/Akt pathway, SNX-2112 inhibits tube formation in human umbilical vein endothelial cells.
In vivo
In a xenograft murine model, SNX-2112 can inhibits MM cell growth and prolongs survival.